Substance: Levotiron Sodium
Pack: 100 tabs (100 mcg/tab)
Levotiron drug is launched by a global database. This indicates that it has not yet reached its final form and may have some errors because it is still being developed. It is not meant to replace the information and advice provided by your physician, pharmacist, or any other qualified healthcare professional. It should in no way be taken to imply that any medication in any country is secure, appropriate, or effective for you to use in any capacity. Before beginning any new treatment, discussing it with your primary care physician is essential.
To evaluate the effect of adding T3 to L-T4 treatment in children with congenital hypothyroidism (CH) who have abnormally elevated levels of thyroid-stimulating hormone (TSH) despite having high normal serum T4 levels while receiving L-T4 treatment to determine whether adding T3 improves the child’s condition.
The research included ten children with CH whose TSH levels were consistently high despite euthyroidism and whose levels would best be normalized with hyperthyroidism. These children had an average age of 7.1 years and a mean age of 2.1 years. T3+L-T4 aggregate treatment was substituted for L-T4 treatment (Bitiron® tablet containing 50 g of L-T4 and 12.5 g of triiodothyronine). The patients received a ratio of four T3 to one L-T4 dose, so they got fifty percent of their regular L-T4 dose as T4 and the other fifty percent as L4. The dose of T3+L-T4 was adjusted to achieve the desired everyday TSH levels. Since the beginning of the study, thyroid hormones, as well as biochemical indicators, have been monitored. The result is that euthyrotropinemia changed in the seventh month (on average) of combined (T3+L-T4) treatment. Compared to treatment with L-T4, combination therapy resulted in a reduction in serum T4 and fT4 and an improvement in T3 levels. In the state of euthyrotropinemia, there was a decrease in LDL-cholesterol and an acceleration in ALP. At hyperthyrotropinemia and euthyrotropinemia, the patient’s vital signs were comparable. Children diagnosed with CH and irrelevant hyperthyrotropinemia can benefit from treatment with T3+L-T4, which results in euthyrotropinemia without developing hyperthyroidism. According to our statistical analysis, persistent hyperthyrotropinemia most likely results from decreased negative feedback due to lower T3 ranges at the pituitary degree.